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Artemether-lumefantrine is the most widely used antimalarial artemisinin-based combination treatment. Recent studies have
suggested that day 7 plasma concentrations of the potent metabolite desbutyl-lumefantrine correlate better with treatment out-
comes than those of lumefantrine. Low cure rates have been reported in pregnant women with uncomplicated falciparumma-
laria treated with artemether-lumefantrine in northwest Thailand. A simultaneous pharmacokinetic drug-metabolite model was
developed based on dense venous and sparse capillary lumefantrine and desbutyl-lumefantrine plasma samples from 116 preg-
nant patients on the Thailand-Myanmar border. The best model was used to evaluate therapeutic outcomes with a time-to-event
approach. Lumefantrine and desbutyl-lumefantrine concentrations, implemented in an Emax model, both predicted treatment
outcomes, but lumefantrine provided better predictive power. A combinedmodel including both lumefantrine and desbutyl-
lumefantrine did not improve the model further. Simulations suggested that cure rates in pregnant women with falciparumma-
laria could be increased by prolonging the treatment course. (These trials were registered at controlled-trials.com [ISRCTN
86353884].)
Approximately half of the worlds’ population is at risk for ma-laria. There were an estimated 584,000 deaths worldwide in
2013 (1). Children below 5 years of age and pregnant women have
the highest risk of malaria infections and mortality (1). On the
Thailand-Myanmar border, there are low seasonal transmission
of Plasmodium falciparum malaria and high levels of antimalarial
drug resistance. Malaria has been an important cause of maternal
mortality and a major factor contributing to low birth weight. As
a result of providing ready access to effective treatment and weekly
antenatal visits to clinics, malaria-related maternal mortality rates
in a stable population of displaced persons have fallen from an
estimated 1,000 per 100,000 (430 to 2,320) in 1985 to zero from
2005 onwards (2). However, in migrants who have less access to
health care, malaria-related maternal mortality has fallen less (2).
Artemisinin-based combination therapy (ACT) is the treat-
ment of choice for uncomplicatedPlasmodium falciparummalaria
in adults and children and also during the second and third tri-
mesters of pregnancy. The oral fixed-dose combination of arte-
mether and lumefantrine (80 mg/480 mg given twice daily for 3
days) is the most commonly used ACT, providing excellent cure
rates in nonpregnant patients (3–8). Artemether-lumefantrine is
considered safe during the second and third trimesters of preg-
nancy, although variable cure rates in this population have been
reported (9–11). High cure rates by day 42 were seen in pregnant
women in Uganda (98.2%; range, 93.5 to 99.7%), but consider-
ably lower cure rates were reported in pregnant women in Thai-
land, where transmission and thus host immunity is substantially
lower (82.0%; range, 74.8 to 89.3%) (9, 10). A substantially
smaller study in Tanzania reported lower cure rates in pregnant
women (18% failures; 6/33 patients) than in nonpregnant women
(5% failures; 1/22 patients) (11). More than 30% of the pregnant
patients in both Thailand and Uganda had day 7 plasma lumefan-
trine concentrations (9, 10) below the previously defined target
concentration of 280 ng/ml (12). Thus, the day 7 concentration of
lumefantrine may not always correlate fully with cure rate, and
variation might be due to ethnicity and/or regional differences as
a consequence of lower background immunity and/or reduced
susceptibility (13).
Lumefantrine’s main metabolite, desbutyl-lumefantrine, has
substantial antimalarial activity (14, 15). Mean half-maximal in-
hibitory concentrations (IC50s) of desbutyl-lumefantrine against
clinical isolates of Plasmodium falciparum in three studies from
northwest Thailand in 1997 and 1998 were 4.38, 6.54, and 8.94
nM, respectively (15). Geometric mean in vitro IC50s of desbutyl-
lumefantrine for laboratory-adapted Plasmodium falciparum par-
asites were 9.0 nM for chloroquine-sensitive (3D7) and 9.5 nM for
chloroquine-resistant (W2mef) cultures (14). Corresponding
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geometric mean IC50s for lumefantrine in the same in vitro exper-
iments were more than five times higher: 65.2 nM and 55.5 nM for
3D7 and W2mef cultures, respectively (14). The mean in vivo ratio
of lumefantrine to desbutyl-lumefantrine exposure was 27.4 [7.0
to 123] in Papua New Guinean children (14). Similar findings
were reported for Colombian patients and pregnant patients in
Thailand (8, 16). Thus, although the metabolite is intrinsically
more potent, the predominant antimalarial effect is provided by
the parent compound. Nevertheless, it has been suggested that
efficacy and pharmacokinetic studies should include measure-
ments of both lumefantrine and desbutyl-lumefantrine to enable
the assessment of a combined parent-metabolite (lumefantrine/
desbutyl-lumefantrine) drug effect (17).
The aim of this study was to assess the population pharmaco-
kinetics and pharmacodynamics of lumefantrine and desbutyl-
lumefantrine using a simultaneous drug-metabolite model in
pregnant women in the second and third trimesters presenting
with uncomplicated Plasmodium falciparum malaria in Thailand.
MATERIALS AND METHODS
Pharmacokinetic data from pregnant patients who had undergone dense
venous sampling (16) and those who had undergone sparse capillary sam-
pling (18), as part of a larger efficacy trial (9) on the northwestern border
of Thailand and Myanmar, were used for the current analysis. Pregnant
patients were enrolled through weekly screening visits at the antenatal
clinic (Shoklo Malaria Research Unit) (19). Initially, inclusion in the trial
(9) was limited to women who had reappearance of Plasmodium falcipa-
rum after quinine monotherapy, the first-line treatment at the time, as
artemether-lumefantrine had never been used to treat uncomplicated ma-
laria in women during pregnancy. The pharmacokinetic and efficacy stud-
ies have been reported previously (9, 16, 18). After review of the first 20
delivered women in the study by the data safety monitoring committee,
the study was then expanded to all patients with Plasmodium falciparum
malaria in the second or third trimester. The study was approved by the
Oxford Tropical Research Ethic Committee, the Ethics Committee of the
Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand,
and the Secretariat Committee on Research Involving Human Subjects of
the World Health Organization.
Patients received standard treatment consisting of 80 mg artemether
and 480 mg lumefantrine (Coartem; Novartis, Basel, Switzerland) twice
daily for 3 days with 200 ml to 250 ml of chocolate milk (i.e., 6 g to 7 g fat).
Frequent venous blood samples (2 ml) were drawn from 13 pregnant
women before the last dose and at 0.5, 1, 2, 4, 6, 8, 12, 24, 48, 72, 96, 120,
144, and 168 h after the last dose (16). Sparse capillary blood from a finger
prick was collected randomly from 103 pregnant women at 0 to 72 h, 72 to
96 h, 96 to 144 h, and 144 to 336 h after the first dose and on day 7 (18).
Blood samples were centrifuged at 2,000  g for 10 min, and the plasma
was stored in cryotubes at 30°C or liquid nitrogen before transfer to
80°C.
Venous plasma concentrations of both lumefantrine and desbutyl-
lumefantrine were quantified by using liquid chromatography with UV
detection (HPLC-UV) (20). Capillary lumefantrine plasma concentra-
tions were initially quantified by using HPLC-UV (20). All capillary sam-
ples were reanalyzed 5 years later for desbutyl-lumefantrine quantifica-
tion using liquid chromatography-tandem mass spectrometry (LC-MS/
MS). The lower limits of quantification for lumefantrine and desbutyl-
lumefantrine were 24 ng/ml and 21 ng/ml, respectively, using HPLC-UV.
For quantification of desbutyl-lumefantrine in capillary samples, a sensi-
tive, specific, and rapid LC-MS/MS method for the determination of lu-
mefantrine and its metabolite desbutyl-lumefantrine was developed and
validated over concentration ranges of 9.7 to 20,000 ng/ml and 1 to 769
ng/ml, respectively, using 100l of plasma. After a simple solvent precip-
itation procedure, separation was achieved using an amide column (2.1
mm by 50 mm, 2.7 m; Advanced Materials Technology, Wilmington,
DE, USA) with a binary gradient solvent system consisting of 2.5 to 10
mM acetonitrile-ammonium acetate at pH 3.5. Mass detection was per-
formed using a triple-quadrupole mass spectrometer (API5000; AB Sciex,
Foster City, CA, USA) operating in positive electrospray ionization mode.
The transition m/z of lumefantrine (528.2 to 276.1) and desbutyl-lume-
fantrine (472.1 to 346.1) was monitored using multiple-reaction moni-
toring. The method did not show any signs of severe ion suppression/
enhancement for lumefantrine or desbutyl-lumefantrine. The within-day
and between-day accuracy and precision at all quality control levels were
below 7%. The coefficients of variation were lower than 8.2% and 7.9%
for all quality control samples during clinical sample analysis using UV
detection and mass spectrometric detection, respectively.
Molar units of lumefantrine and desbutyl-lumefantrine plasma con-
centrations were transformed into their natural logarithms and modeled
simultaneously using a linear drug-metabolite model. Estimations and
simulations were performed using NONMEM v.7.2 (ICON Development
Solutions, Ellicott City, MD) with a G-Fortran compiler (Free Software
Foundation, Boston, MA) on a Windows 7 operating system (Microsoft
Corporation, Seattle, WA). Subroutine ADVAN6 was used for pharma-
cokinetic and pharmacodynamic model building, and the first-order con-
ditional estimation method with interaction and the Laplacian estimation
method with interaction were used to model the pharmacokinetic and
pharmacodynamic data, respectively (21). Postprocessing and automa-
tion was done using Pearl-Speaks-NONMEM (PsN) v. 3.5.3 (22, 23),
Xpose v. 4 (24), and R v. 2.15.1 (The R Foundation for Statistical Com-
puting).
The objective function value (OFV; proportional to minus twice the
log-likelihood of the data) was used to evaluate competing models during
the model building process. A drop in OFV of 3.84 or more was consid-
ered a significant (P 0.05) improvement between two hierarchical mod-
els after inclusion of one additional parameter (one degree of freedom).
Goodness-of-fit diagnostics and physiological/pharmacological plausibil-
ity were also considered during the model building process.
A simultaneous population pharmacokinetic model for lumefantrine
and desbutyl-lumefantrine was constructed. Different absorption (first-
order and first-order with lag-time absorption), distribution (one-, two-,
and three-compartment distribution), variability (between-subject vari-
ability) and residual error (additive, proportional, and combined additive
and proportional errors on log-transformed data) models were consid-
ered. Model parameters were assumed to be log-normally distributed
(equation 1), although a Box-Cox transformed distribution (equation 2)
was also evaluated for relative bioavailability (25).
(1)
Pi PTV  e

Pi PTV  e
e
1
 (2)
Pi represents the individual parameter estimate, PTV represents the typical
parameter estimate for the population,  represents the between subject
variability in the data, and  represents the estimated Box-Cox transfor-
mation factor.
The differences in biological matrix (i.e., capillary versus venous data)
might be explained partly by different quantification methods (i.e.,
HPLC-UV and LC-MS/MS). However, a correction factor embedded on a
population level did not allow us to differentiate between differences re-
sulting from the analytical quantification assay method and the biological
matrix (for HPLC-UV, the lumefantrine venous and capillary matrix as
well as the desbutyl-lumefantrine venous matrix; for LC-MS/MS, the des-
butyl-lumefantrine capillary matrix) (13). For desbutyl-lumefantrine, it is
even more complex to dissect the contribution due to potential stability
issues over 5 years. The covariates body weight, estimated gestational age,
and parasitemia were tried sequentially on all pharmacokinetic parame-
ters using linear (equation 3), exponential (equation 4), and power (equa-
tion 5) relationships. Stepwise covariate modeling was applied using P
values of 0.05 (OFV 3.84) and 0.001 (OFV 10.83) as cutoff criteria
in the forward step and backward step, respectively.
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Pi PTV  [1  (covariate valuemedian value)] e
 (3)
Pi PTV  e
(covariate valuemedian value)  e (4)
Pi PTV  (covariate value ⁄ median value)
  e (5)
The best pharmacokinetic drug-metabolite model was fixed and used
to evaluate the pharmacodynamic properties with a time-to-event ap-
proach. Constant (equation 6), Weibull (equation 7), and Gompertz
(equation 8) hazard models were evaluated to describe recrudescent ma-
laria.
h(t)  (6)
h(t) 	2   t	1 (7)
h(t)  et
ln(2)
t1⁄2 (8)
The hazard at a certain time point is described by h(t), 	 represents the
(baseline) hazard estimate, t represents the time, 
 represents the shape
parameter in the Weibull distribution, and t1/2 represents the elimination
half-life of the hazard in the Gompertz model.
Patients were screened weekly for malaria; and the start of the interval
censoring time was therefore set to the time of the last parasite-negative
visit, and the end of the interval was set to the time of the visit when
recrudescent malaria was detected. This allows the event to take place at
any time during the interval time and is not fixed to the time when the
patients visited the clinic (equation 9).
P(event) 1 e(h(t)eventh(t)start interval) (9)
Lumefantrine and desbutyl-lumefantrine drug effects were evaluated
using a sigmoidal Emax model (equation 10), where the slope factor ()
was fixed to 1 and also estimated.
E E0 
C
  Emax
EC50

  C

(10)
Drug effects (E) were evaluated using individually predicted lumefan-
trine or desbutyl-lumefantrine plasma concentration (C), where E0 is the
baseline effect (fixed to 1), Emax is the maximum effect (fixed to 1), and
EC50 is the concentration realizing half of the maximum effect. Cumula-
tive areas under the plasma concentration-time curves of lumefantrine or
desbutyl-lumefantrine were also evaluated instead of predicted plasma
concentrations. A stepwise covariate modeling procedure was performed
on the pharmacodynamic parameters (i.e., baseline hazard and hazard
half-life). Body weight, estimated gestational age, primary gravidity, age,
parasitemia, and admission infection (i.e., malaria infection type at the
start of the study; recrudescent or novel infection after previous treat-
ment, or primary new infection) were tested as categorical covariates or as
continuous covariates using an exponential relationship. P values of 0.05
and 0.001 were used as significance cutoff criteria during the forward and
backward steps, respectively.
New malaria infections were modeled using a constant hazard model
with interval censoring. The interval was based on observed parasitemia at
detection and the back-calculated plausible interval of parasite release
from the liver (hepatic schizogony) by using fixed high (10-fold increase
in parasitemia every 48 h, with the assumption of 105 parasites released
from the liver) and low (5-fold increase in parasitemia every 48 h, 104
parasites released from the liver) multiplication rates (26). Consequently,
an event represents the appearance of asymptomatic malaria instead of
the time of microscopy detection (symptomatic malaria), which could be
potentially later due to travel time to the hospital and/or disregarding of
the symptoms by the patient. Individually predicted lumefantrine and
desbutyl-lumefantrine plasma concentrations were evaluated as modula-
tors on the constant hazard function using a sigmoidal Emax model, with 
being estimated or fixed to 1.
The robustness of parameter estimates from the final model was as-
sessed by calculation of relative standard errors and the 95% confidence
intervals of parameter estimates from nonparametric bootstrap diagnos-
tics (n 1,000). The predictive power of the model was assessed by using
visual predictive checks (27). For the pharmacokinetic data, simulations
and observations were corrected for population predictions, and results
were visualized by overlaying the 95% confidence intervals of the simu-
lated (n  2,000) 5th, 50th, and 95th percentiles with the 5th, 50th, and
95th percentiles of the observed data. The visual predictive check for the
time-to-event analysis was visualized by overlaying the 95% confidence
interval from the simulated (n  2,000) events with the observed data.
The visual predictive check for the relative hazard (compared to the base-
line hazard) was visualized by overlaying the simulated (n 2,000) 90%
confidence interval with the estimated relative hazard and observed lume-
fantrine or desbutyl-lumefantrine plasma concentrations. The reliability
of individual parameter estimates and goodness-of-fit plots were assessed
by the calculation of eta and epsilon shrinkage (28).
Monte Carlo simulations (n 2,000) were performed using the final
population pharmacokinetic-pharmacodynamic model to assess the
treatment outcome after a standard dose regimen (80 mg artemether/480
mg lumefantrine twice daily for 3 days), 80 mg artemether/480 mg lume-
fantrine twice daily for 5 days (18), and 80 mg artemether/480 mg lume-
fantrine twice daily for 10 days. The 10-day regimen was evaluated only in
order to challenge the (full Emax) model and would not be feasible in the
clinic due to adherence issues. An increased and extended dose regimen
(100 mg artemether/600 mg lumefantrine twice daily for 4 days; trial
registry no. NCT01054248 [ClinicalTrials.gov]) was also evaluated, and
for this simulation scenario, bioavailability was assumed to be reduced by
7.5% because of dose-limited absorption (5). Results were presented with
box (25% to 75%) and whisker (2.5% to 97.5%) plots (GraphPad Soft-
ware, Inc., CA, USA) for the simulated percentage of recrudescence-free
(presumed cured) patients at day 42, day 7 lumefantrine plasma concen-
trations, and day 7 desbutyl-lumefantrine plasma concentrations.
RESULTS
This pooled analysis was conducted using data from a previously
reported study in pregnant women where dense venous (n 13)
and sparse capillary (n 103) samplings were embedded in a large
drug efficacy trial (Table 1) (16, 18). Seventeen of these 116
women had PCR confirmed recrudescent infections, 22 had novel
infections during follow-up, and 77 had no parasite reappearance
during the 42 days of follow-up or until delivery (Table 1). The
median (range) time to recrudescent malaria was 23 (14 to 63)
days. The median time to novel malaria infection was 35 (15 to
140) days (Table 1).
A two-compartment drug-metabolite model using first-or-
der absorption with lag time was used to describe simultane-
ously the lumefantrine and desbutyl-lumefantrine pharmaco-
kinetic data (Fig. 1). The addition of additional distribution
compartments did not result in a significant improvement in
the model fit. Implementation of relative bioavailability signif-
icantly improved the model fit (OFV284) and a Box-Cox
transformation on relative bioavailability (OFV  4.86)
was needed to correct for a systemic under prediction in the
diagnostic plots (Fig. 2). A correction factor was implemented
at a population level to correct for concentration differences
between measurements in venous and capillary plasma (Table 2).
Different random additive residual variability components were
implemented for venous and capillary samples for both lumefan-
trine and desbutyl-lumefantrine (Table 2).
Body weight in a power relation with all clearance (exponent
fixed to 0.75) and distribution (exponent fixed to 1) parameters
did not improve the model fit. The covariates parasitemia (linear
on lumefantrine elimination clearance, exponential on desbutyl-
lumefantrine elimination clearance, and exponential on desbutyl-
lumefantrine central apparent volume of distribution) and esti-
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mated gestational age (power relationship on the absorption rate
constant, linear on lumefantrine intercompartmental clearance,
exponential on lumefantrine peripheral apparent volume of dis-
tribution, exponential on desbutyl-lumefantrine central apparent
volume of distribution, exponential on lumefantrine elimination
clearance, linear on desbutyl-lumefantrine elimination clearance,
and exponential on desbutyl-lumefantrine intercompartmental
clearance) were selected during the forward step of the stepwise
covariate modeling (P  0.05). However, only parasitemia on
desbutyl-lumefantrine elimination clearance and estimated gesta-
tional age on the absorption rate constant and lumefantrine inter-
compartmental clearance could be retained in the backward step
of the stepwise covariate modeling (P 0.001).
The basic goodness-of-fit plots showed accurate and precise
predictions of the lumefantrine and desbutyl-lumefantrine con-
centrations (Fig. 2). Desbutyl-lumefantrine plasma concentration
data below the limit of quantification in the terminal elimination
phase did not result in any major model misspecification. The
prediction-corrected visual predictive check (n 2,000) indicated
adequate predictive power for lumefantrine and desbutyl-lume-
fantrine plasma concentrations (Fig. 3). Eta shrinkage was high
and ranged between 28.1% and 45.5%. Epsilon shrinkage was
4.76% for venous lumefantrine, 21.0% for capillary lumefantrine,
3.90% for venous desbutyl-lumefantrine, and 28.8% for capillary
desbutyl-lumefantrine. Final model-derived pharmacokinetic pa-
rameter estimates and secondary estimates are presented in Tables
2 and 3, respectively.
Pharmacokinetic parameters were fixed to the final estimates,
and pharmacokinetic-pharmacodynamic data were fitted simul-
taneously (Table 4). Interval censoring for the weekly screening
was implemented for recrudescent malaria. A Gompertz hazard
model performed better compared to a constant (OFV 
8.00) or Weibull (OFV 10.0) hazard model. Both desbu-
tyl-lumefantrine (OFV  5.19) and lumefantrine (OFV 
7.17) plasma concentrations had a significant effect on the haz-
ard of recrudescent malaria using an Emax model with the slope
factor fixed to 1. However, lumefantrine contributed the larger
effect, and an additive drug effect of desbutyl-lumefantrine did
not further improve the model fit. Estimated gestational age (ex-
ponential on baseline hazard and hazard elimination half-life) and
body weight (exponential on baseline hazard) were all selected as
significant covariates during the forward addition step of the step-
wise covariate modeling (P  0.05). However, none of these co-
variates could be retained in the backward elimination of selected
covariates (P 0.001). Admission malaria type (i.e., recrudescent
infection, novel infection, or primary new malaria) as a covariate
on baseline hazard, hazard half-life, or lumefantrine IC50 did not
significantly improve the model fit either. The median (range;
quantile range) individually predicted lumefantrine concentra-
tions at day 7 and area under the concentration-time curve from
zero to infinity (AUC0 –) in patients with recrudescent malaria on
admission (431 [121 to 1,650; 303 to 545] ng/ml and 541 [167 to
1,330; 367 to 694] g · h/ml) or novel malaria (439 [140 to 933;
307 to 528] ng/ml and 528 [244 to 892; 384 to 636] g · h/ml)
tended to be only slightly lower than in patients with admission
primary new malaria infections (469 [158 to 1,210; 326 to 710]
ng/ml and 595 [157 to 1,340; 474 to 804]g · h/ml), but it did not
reach statistical significance (P  0.05; analysis of variance
[ANOVA] and regression analysis on logarithmically transformed
day 7 and AUC).
The 90% confidence interval of 2,000 simulated Kaplan-
Meier plots described the observed recrudescent malaria accu-
rately using either lumefantrine or desbutyl-lumefantrine as
drug effects (Fig. 4A and B). However, the 90% confidence
interval of relative hazard versus plasma concentration indi-
TABLE 1 Demographic summary of the study populationa
Parameter All data Dense sampling (16) Sparse sampling (18)
Study size 116 13 103
Number of PK samples (LF/DLF) 688/517 207/175 481/342
Number of PK samples per patient (LF/DLF) 5 (1–16)/4 (1–16) 16 (15–16)/16 (15–16) 5 (1–5)/4 (1–5)
Age (yr) 24 (14–42) 20 (14–42) 24 (15–42)
Body wt (kg) 49.0 (35.0–65.0) 47.0 (41.0–57.0) 49.0 (35.0–65.0)
Body temp (°C) 36.7 (35.0–39.3) 36.0 (35.0–38.5) 36.7 (35.0–39.3)
Estimated gestational age (weeks) 22.8 (13.1–39.0) 23.0 (13.1–38.0) 22.6 (13.1–39.0)
Primiparity (%) 23.4 31.0 22.3
Parasitemia (/l) 3,260 (56.8–154,000) 837 (91–251,000) 4,400 (57.0–154,000)
No parasite reappearance (%) 66.4 92.3 63.1
New infections (%) 19.0 7.69 20.4
Time to new infections (days) 35 (15–140) 21 35 (15–140)
Recrudescent infections (%) 14.7 0 16.5
Time to recrudescent infections (days) 23 (14–63) 23 (14–63)
a Values are presented as medians (ranges) unless otherwise stated. PK, pharmacokinetics; LF, lumefantrine; DLF, desbutyl-lumefantrine.
FIG 1 Visual representation of the structural population pharmacokinetic-
pharmacodynamic model for lumefantrine/desbutyl-lumefantrine. LF, lume-
fantrine; DLF, desbutyl-lumefantrine; ka, absorption rate constant; VC/F, ap-
parent central volume of distribution; VP/F, apparent peripheral volume of
distribution;Q/F, intercompartmental clearance; CL/F, elimination clearance;
and Hz(t), hazard function.
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cated a better predictive power for the model using lumefan-
trine as a predictor of outcome than for that using desbutyl-
lumefantrine (Fig. 4C and D).
Novel infections could be described using a constant hazard
model with interval censoring, based on a back-calculated time
interval representing the approximated start of the parasite blood
stage. The implementation of a lumefantrine or desbutyl-lume-
fantrine drug effect (Emax and sigmoidal Emax) on the constant
hazard model did not improve the model fit significantly.
Monte-Carlo simulations (n  2,000) were performed using
the final pharmacokinetic-pharmacodynamic model for a twice-
daily artemether-lumefantrine treatment (with four tablets at
each occasion) for 3 days, 5 days, and 10 days and a twice-daily
dosing regimen with 5 tablets per dosing occasion for 4 days. Not
surprisingly, simulated lumefantrine and desbutyl-lumefantrine
concentrations at days 7 and 14 and day 42 cure rates increased
with extended treatment duration (Fig. 5).
DISCUSSION
Artemether-lumefantrine is the most widely used artemisinin
combination treatment and is also the most widely used in preg-
nancy. Artemether provides rapid parasite killing and therefore
rapid recovery, whereas lumefantrine removes the parasites that
remain after two parasite asexual cycles have been exposed to arte-
mether. Lumefantrine is metabolized to an active metabolite, des-
butyl-lumefantrine. In this large series of 116 pregnant patients
studied on the Thailand-Myanmar border, lumefantrine and des-
butyl-lumefantrine pharmacokinetic data were analyzed simulta-
neously. The developed model allowed characterization of the
pharmacokinetic-pharmacodynamic relationship for both lume-
fantrine and desbutyl-lumefantrine.
Pharmacokinetics. Lumefantrine absorption and disposition
pharmacokinetics were best described using first-order absorp-
tion with lag-time followed by a two-compartment distribution
model (Fig. 1). This was identical to the previously performed
pharmacokinetic analysis of the sparsely sampled capillary lume-
fantrine data (18). Desbutyl-lumefantrine was best described us-
ing two disposition compartments, as previously shown in Papua
New Guinean children (17). Estimated gestational age as a cova-
riate on intercompartmental clearance of lumefantrine corre-
sponds with previously published findings in pregnant and non-
pregnant women in Uganda, where pregnancy as a categorical
covariate was a significant covariate in intercompartmental clear-
ance (13). Estimated gestational age as a covariate on ka, resulting
in a reduced ka with increasing gestational age, could be explained
by decreased gut motility during pregnancy (29–31). Admission
parasitemia correlated significantly with desbutyl-lumefantrine
elimination clearance, resulting in a higher clearance for patients
with higher parasitemia on admission. However, the mechanism
underlying this covariate relationship is not known. The final
population pharmacokinetic model showed a good predictive
performance and goodness-of-fit diagnostics for lumefantrine
and desbutyl-lumefantrine.
Pharmacodynamics. Pharmacokinetic parameters were fixed
in the pharmacokinetic-pharmacodynamic model, and the cho-
sen approach resulted in an adequate fit of observed data for re-
crudescent malaria (Fig. 4). Pharmacokinetic artemether and
dihydroartemisinin measurements were available for only 13 pa-
FIG 2 Goodness-of-fit diagnostics from the final pharmacokinetic model for lumefantrine (A to D) and desbutyl-lumefantrine (E to H). (A and E) Observed
plasma concentration versus population predicted plasma concentrations; (B and F) observed plasma concentrations versus individual predicted plasma
concentrations; (C and G) conditional weighted residuals versus time after dose; (D and H) conditional weighted residuals versus population predicted plasma
concentration. The black solid lines, black dashed lines, and open circles represent the line of identity, the trend line, and observations, respectively. Two
lumefantrine and desbutyl-lumefantrine baseline values were excluded for the diagnostic plots, as they were predicted to be 0.
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tients in the dense-venous-sampling study arm and therefore not
modeled separately and embedded in the overall pharmacoki-
netic-pharmacodynamic model. Furthermore, none of these 13
patients had recrudescent infections, although this could have
been a result of lower parasitemia at admission, as these patients
had recrudescent infections after quinine treatment. The pharma-
cokinetic-pharmacodynamic relationship between lumefantrine
or desbutyl-lumefantrine and treatment outcome in the devel-
oped model therefore represents the sum of antimalarial activities
of artemether, dihydroartemisinin, lumefantrine, and desbutyl-
lumefantrine. However, recrudescent malaria is more correlated
to partner drug exposure as previously described for dihydroarte-
misinin-piperaquine (32). An Emax model, with an estimated
slope factor, for both lumefantrine and desbutyl-lumefantrine re-
sulted in a significant improvement of the model fit but it was not
considered superior to an Emax model, with the slope fixed to 1,
due to the instability of the model (100% different slope factors
with different initial estimates). A possible explanation for the
poor stability might be the small number of recrudescent malaria
episodes (17 out of 116 observations) during the follow-up pe-
riod. Lumefantrine and desbutyl-lumefantrine plasma concentra-
tions could be used interchangeably as predictors for recrudescent
malaria, which might be explained by the similarity in pharmaco-
kinetic concentration-time profiles. However, desbutyl-lumefan-
trine concentrations were substantially lower, which explains the
lower IC50 for desbutyl-lumefantrine than for lumefantrine. In
this study, lumefantrine showed a better predictive power than
desbutyl-lumefantrine, which might be a result of more accurate
and precise predictions of lumefantrine than desbutyl-lumefan-
trine concentrations by the developed model (Fig. 4C and D).
Therefore, lumefantrine concentrations were used in this model
for in silico dose optimizations. Admission malaria type (i.e., re-
crudescent, novel, or primary new infection) did not improve the
model fit significantly in this analysis. However, a previously pub-
lished clinical analysis (9) showed a lower efficacy in women en-
rolled with recrudescent or novel infections compared to the
women enrolled with primary new infections. Since the differ-
ences in lumefantrine concentrations between the groups were
very small, other reasons, including different background immu-
nity in these patients, cannot be excluded as possible explanations
for this varying efficacy.
Although the study was not designed to evaluate the prophy-
lactic effect of artemether-lumefantrine, neither lumefantrine nor
desbutyl-lumefantrine plasma concentrations significantly sup-
pressed novel infections in pregnant women on the Thailand-
Myanmar border, an area of low and seasonal transmission. Lu-
mefantrine has a relatively short half-life (3.3 days) and so exerts
TABLE 3 Secondary population parameter estimates
Secondary
parameter
Median value (range)
Lumefantrine
Desbutyl-
lumefantrine
Day 7 concn (ng/ml) 436 (81.2–1,650) 30.3 (7.55–91.8)
AUC0- (h · g/ml) 552 (114–1,340) 12.2 (3.18–37.3)
Cmax (ng/ml) 6,660 (1,440–15,800) 73.2 (18.7–192)
Tmax (h) 5.88 (2.50–13.1) 14.4 (9.07–42.4)
t1/2 (days) 3.65 (2.81–7.59) 4.08 (2.93–6.21)
TABLE 2 Primary population parameter estimates from the final pharmacokinetic-pharmacodynamic model
Primary parametera Population estimateb (% RSEc) 95% CId % CV for IIVb (% RSEc) 95% CId
ka (h
1) 0.0577 (7.93) 0.0526–0.0655
Lag time (h) 1.31 (43.6) 0.0131–2.05
F (%) 100 (fixed) 51.2 (14.3) 42.7–58.3
Box-Cox shape parameter on F 0.394 (48.3) 0.765 to 0.0279
CLLF/F (liters/h) 5.35 (12.9) 4.11–6.77 11.2 (49.5) 3.20–15.7
VC LF/F (liters) 28.4 (26.8) 17.3–46.8 119 (29.4) 78.1–178
QLF/F (liters/h) 1.55 (13.9) 1.17–2.00 23.9 (45.2) 9.14–33.7
VP LF/F (liters) 147 (13.9) 110–187
CLDLF/F (liters/h) 197 (11.5) 156–245 23.2 (59.1) 6.93–36.5
VC DLF/F (liters) 6,490 (21.1) 3,460–8,970 90.5 (93.9) 44.8–181
QDLF/F (liters/h) 250 (19.1) 183–369
VP DLF/F (liters) 13,200 (12.6) 10,500–16,900
LF capillary conversion factor 0.878 (13.2) 0.667–1.12
DLF capillary conversion factor 0.464 (11.5) 0.371–0.585
Parasitemia exponentiallye on CLDLF 0.133 (31.8) 0.0455–0.210
EGA powere on ka 0.715 (19.1) 0.972 to 0.474
EGA lineare on QLF (%) 2.71 (22.8) 3.59 to 1.34
 venous LF 0.252 (54.0) 0.0208–0.550
 capillary LF 0.0464 (15.4) 0.0332–0.0598
 venous DLF 0.335 (52.7) 0.0178–0.639
 capillary DLF 0.0326 (18.9) 0.0213–0.0458
a LF, lumefantrine; DLF, desbutyl-lumefantrine; Box-Cox shape parameter, shape parameter on Box-Cox transformation; ka, absorption rate constant; VC/F, apparent central
volume of distribution; VP/F, apparent peripheral volume of distribution; Q/F, inter-compartmental clearance; CL/F, elimination clearance; , variance of the unexplained residual
variability.
b Population mean values and inter-individual variability (IIV) estimated by NONMEM. Coefficient of variation (% CV) for IIV is calculated as 100eestimate1.
c Relative standard error (RSE) is calculated as 100  (standard deviation/mean parameter estimate) from 1,000 iterations of a nonparametric bootstrap diagnostics.
d The 95% confidence interval (95% CI) is displayed as the 2.5 to 97.5 percentiles of the bootstrap estimates.
e Exponential covariate relationship is determined as exp{ [covariate  median(covariate)]}; power covariate relationship is determined as [covariate/median(covariate)]; linear
covariate relationship is determined as 1  { [covariate  median(covariate)]}.
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considerably less posttreatment prophylactic activity than meflo-
quine or piperaquine (33).
Dose optimizations. In silico dose optimizations displayed
substantially increased lumefantrine exposures at day 7 and day 14
with the extended dose regimens. However, the relative improve-
ment of the simulated cure rates at day 42 with extended treat-
ments compared to the standard treatment was small. This could
be explained by a failure to estimate a slope factor in the Emax
model and/or the absence of the artemether/dihydroartemisinin
drug effects in this model. Furthermore, relatively high eta shrink-
age was observed, but it should not affect model mean predictions
but only the simulated variability in the population. The model
clearly underpredicted treatment success rates at day 42 after pro-
longed treatment, as the model does not adequately take into ac-
count the additional parasite killing provided by a longer course of
artemether in this fixed combination. Prolonged artemether treat-
ment will result in additional drug exposure in subsequent para-
site life cycles, leaving a lower parasite density to be killed by lu-
mefantrine. It is therefore important in future studies to dissect
the artemether/dihydroartemisinin and lumefantrine/desbutyl-
lumefantrine drug effects with respect to outcome to fully opti-
mize the treatment. Indeed, a seven-day course of artemether
alone provided 94% curative efficacy in earlier studies of recrudes-
cent malaria in nonpregnant patients in this region, substantiating
an increased killing of parasites when parasites are exposed to
artemisinins for a sustained number of life cycles (34). A pro-
longed lumefantrine treatment will of course have similar effects,
with a sustained killing of parasites in subsequent life cycles.
Simulations performed here of prolonged treatments using the
developed model assumed a time-independent lumefantrine and
desbutyl-lumefantrine pharmacokinetics. Previous studies have
reported dose-limited lumefantrine absorption, where patients
receiving a single daily lumefantrine dose for 3 days displayed 30%
lower exposure than patients receiving the same total dosage split
into two lumefantrine doses per day for 3 days (5). Therefore, a
7.5% decreased relative bioavailability was assumed for simula-
tions of a 25% increased dosage (i.e., linearly extrapolated from
30% decreased bioavailability after a double dose). However, ex-
tending the dose regimen with additional days of dosing might
result in additional alterations in the absorption of lumefantrine,
and simulations should therefore be interpreted with caution.
Other factors rather than solely pharmacokinetic exposures
might have an impact on the treatment outcome. For example,
host immune responses are reduced during pregnancy, and this
FIG 3 Prediction-corrected visual predictive checks (n 2,000) for lumefantrine (A) and desbutyl-lumefantrine (B). The black circles represent the observa-
tions, the black solid lines represent the 5th, 50th, and 95th percentiles of the observed data, and the gray shaded areas represent the 90% confidence intervals of
the simulated 5th, 50th, and 95th percentiles.
TABLE 4 Time-to-event analysis
Parameter
Lumefantrine drug effect Desbutyl-lumefantrine drug effect
Population estimatea
(% RSEb) 95% CIc
Population estimatea
(% RSEb) 95% CIc
Baseline hazard (recrudescent
infections per week)
0.0845 (43.4) 0.0411–0.219 0.105 (36.7) 0.0496–0.223
Hazard half-life (h) 400 (23.9) 233–606 233–606 247–522
IC50 (ng/ml) 169 (44.0) 32.1–296 7.05 (43.9) 1.49–15.1
a Population mean values estimated by NONMEM.
b Relative standard error (RSE) is calculated as 100  (standard deviation/mean parameter estimate) from 1,000 iterations of nonparametric bootstrap diagnostics.
c The 95% confidence interval (95% CI) is displayed as the 2.5 to 97.5 percentiles of the bootstrap estimates.
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potentially means that a different lumefantrine day 7 concentra-
tion threshold is required in this special population. However, this
is difficult to dissect and quantify, since ethnicity and geographical
region might play a major role in the immune response. Further-
more, resistance to artemisinin derivatives in Southeast Asia in-
creasingly compromises treatment efficacy, as this increases the
number of residual parasites which have to be cleared by lumefan-
trine.
The most important issues at this point are to understand the
underlying source of the reduced efficacy of artemether/lumefan-
trine during pregnancy on the Thailand-Myanmar border and to
determine whether adequate dose optimization can decrease the
risk of treatment failures and resistance development. This could
be of great importance in anticipating a future scenario of reduced
efficacy in Africa. Indeed, lower drug exposures and cure rates in
pregnant women than in nonpregnant women have been shown
in Tanzania, but cure rates remained high in Uganda even though
drug exposures were also substantially lower during pregnancy
(10, 11, 13). Overall, the lack of pharmacokinetic and efficacy
studies in pregnant women in both Asia and Africa bring into
question the dosing strategies in this group. Therefore, sufficiently
powered studies with an equally sized nonpregnant control group
and frequent pharmacokinetic (lumefantrine/desbutyl-lumefan-
trine and artemether/dihydroartemisinin plasma concentration)
FIG 4 Visual predictive check (n 2,000) for the time-to-event survival analysis with lumefantrine drug effect (A) and desbutyl-lumefantrine drug effect (B).
Visual predictive check (n 2,000) for relative hazard of recrudescent malaria compared to the baseline hazard versus lumefantrine plasma concentrations (C)
and desbutyl-lumefantrine plasma concentrations (D). The open circles represent observed concentrations and corresponding estimated relative hazards, and
the solid and dashed lines represent the median and the 5th and 95th percentiles of 2,000 simulations using the final pharmacokinetic-pharmacodynamic model.
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and pharmacodynamic samples (parasite clearance time and
treatment outcome) are urgently needed. The continued use of
the currently recommended doses of this drug combination in
pregnant women might result in increased failure rates and the
spread of drug-resistant parasites due to subtherapeutic lumefan-
trine levels.
In conclusion, a simultaneous drug-metabolite model was de-
veloped which adequately described the pharmacokinetic proper-
ties of lumefantrine and desbutyl-lumefantrine. The pharmaco-
dynamic data were modeled using a time-to-event model linked
to the pharmacokinetic model. Lumefantrine and desbutyl-lume-
fantrine could be used interchangeably as predictors of treatment
failure, but lumefantrine realized a better predictive power in this
model. An additive drug effect of desbutyl-lumefantrine did not
further improve the model fit. The simulations based on the cur-
rent lumefantrine/desbutyl-lumefantrine drug effect model,
which contains substantial limitations, indicated that the drug
combination of artemether and lumefantrine with the standard
dosing regimen has suboptimal efficacy on the Thailand-Myan-
mar border in the treatment of uncomplicated Plasmodium falcip-
arummalaria during the second and third trimesters of pregnancy
and that increased treatment duration may facilitate improved
cure rates.
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